A5007170568- Advanced Radiotherapy Techniques
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Meningioma and schwannoma management
- Management of metastatic bone disease
- Renal cell carcinoma treatment
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Prostate Cancer Treatment and Research
- Radiation Therapy and Dosimetry
- Head and Neck Surgical Oncology
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiation Dose and Imaging
- Vascular Malformations Diagnosis and Treatment
New York University
2023-2025
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2024-2025
NYU Langone Health
2022-2024
Geisinger Neuroscience Institute
2018-2023
Geisinger Medical Center
2019-2022
Geisinger Health System
2018-2022
Beth Israel Deaconess Medical Center
2011-2021
Cancer Institute (WIA)
2021
Radiation Oncology Associates
2015-2020
University of California, San Diego
2020
Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable surgery. We investigated factors associated with clinical outcomes treated SBRT from a multi-center, international patient registry.Patients were identified the RSSearch® Patient Registry. Patient, tumor and characteristics assessed. Dose fractionations normalized to BED10. Overall survival (OS) local control (LC) evaluated using Kaplan Meier analysis log-rank test.The study...
BACKGROUND Stereotactic ablative radiotherapy (SABR) is an emerging therapy for primary renal cell carcinoma. The authors assessed safety, efficacy, and survival in a multi‐institutional setting. Outcomes between single‐fraction multifraction SABR were compared. METHODS Individual patient data sets from 9 International Radiosurgery Oncology Consortium Kidney institutions across Germany, Australia, the United States, Canada, Japan pooled. Toxicities recorded using Common Terminology Criteria...
Unresectable intrahepatic and hilar cholangiocarcinomas carry a dismal prognosis. Systemic chemotherapy conventional external beam radiation brachytherapy have been used with limited success. We explored the use of stereotactic body radiotherapy (SBRT) for these patients.Patients unresectable or cholangiocarcinoma those positive margins were included in this study. therapy was at discretion medical oncologist. The Cyberknife(TM) system to treat patients. Patients treated three daily...
<h3>Background</h3> Ipilimumab improves survival in metastatic melanoma patients. This population frequently develops brain metastases, which have been associated with poor and are often treated radiation. Therefore, outcomes following ipilimumab radiation of interest, especially given case reports animal studies suggest combined treatment may generate abscopal responses outside the field. <h3>Findings</h3> We reviewed sixteen consecutive patients who received 1 to 8 courses radiation, a sum...
The epidemiology and natural history of adult gliosarcomas (GSMs), as well patient treatment factors associated with outcome, are ill defined. Patients over 20 years age GSM diagnosed from 1988 to 2004 were identified in the Surveillance, Epidemiology, End Results (SEER) database. Kaplan-Meier survival analysis Cox models used examine outcomes. Similar analyses conducted for patients glioblastoma (GBM) same time period. represented 2.2% 16,388 either or GBM. No significant differences...
Abstract BACKGROUND: A randomized phase 2 study was performed to investigate the efficacy/toxicity of combining concomitant boost radiation and weekly carboplatin/paclitaxel with or without amifostine in patients locally advanced squamous cell carcinoma head neck (SCCHN). METHODS: Patients newly diagnosed, stage III IV SCCHN received 4 doses carboplatin (area under curve, 1.5) paclitaxel (45 mg/m ) concurrently consisting 72 grays 42 fractions over 6 weeks (every day for 18 days, twice a 12...
To evaluate spectral computed tomography (CT) with metal artifacts reduction software (MARS) for of associated gold fiducial seeds.Thirteen consecutive patients 37 seeds implanted radiation therapy abdominal lesions were included in this HIPAA-compliant, institutional review board-approved prospective study. Six women (46%) and seven men (54%). The mean age was 61.1 years (median, 58 years; range, 29-78 years). Spectral imaging used arterial phase CT. Images reconstructed without MARS axial,...
Aim: To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma. Materials & methods: Eight international institutions completed 65-item survey covering patient selection, planning/treatment aspects and response evaluation. Results: All centers treat patients with pre-existing hypertension solitary kidneys. Five apply size constraints 5–8 cm. The total planning target volume expansion is 3–10 mm. perform pretreatment imaging...
The purpose of this study was to evaluate treatment patterns and outcomes stereotactic body radiotherapy (SBRT) for centrally located primary non-small cell lung cancer (NSCLC) or metastases from the RSSearch® Patient Registry, an international, multi-center patient registry dedicated radiosurgery SBRT. Eligible patients included those with tumors clinically staged T1-T2 N0, M0, biopsy-confirmed NSCLC treated SBRT between November 2004 January 2014. Descriptive analysis used report...